OCT 1 6 2007

Docket No.

284394US0PCT

ItW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Antoni TORRENS JOVER, et al.

SERIAL NO:

10/566,399

GAU:

1614

FILED:

September 26, 2006

EXAMINER:

FOR:

2-'4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3-YL) - ACETAMINE

DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE

TREATMENT OF OBESITY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the reference(s) listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,


OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03) Jay E. Rowe, Jr. Registration No. 58, 948



AND TRADEMARK OFFICE IN THE UNITED STATES

IN RE APPLICATION OF:

Antoni TORRENS JOVER, et al.

SERIAL NO: 10/566,399

GROUP: 1614

FILED:

September 26, 2006

EXAMINER:

FOR:

2-'4-(HYDROXYMETHYL-PHENYLAMINO) -PIPERIDINE-1-YL!-N- (9H-CARBAZOL-3-YL) - ACETAMINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROPEPTIDE Y5 (NPY5) LIGANDS FOR THE

TREATMENT OF OBESITY

STATEMENT OF RELEVANCY

References AW to AYon Form PTO-1449 are discussed in the specification.